Approved Diagnostic Test Differentiates Between HIV Infection Types
By LabMedica International staff writers Posted on 11 Aug 2015 |
Image: Bio-Rad BioPlex 2200 HIV Ag-Ab assay pack (Photo courtesy of Bio-Rad Laboratories).
A diagnostic assay has been approved that differentiates between Human immunodeficiency virus 1 (HIV-1) antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.
Two major types of HIV have been identified: HIV-1 and HIV-2. HIV-1 is responsible for most HIV infections throughout the world. HIV-2 is found primarily in West Africa; however, cases of HIV-2 infection have been identified in the USA. HIV-1 and HIV-2 are similar, but distinct viruses.
HIV antigens and antibodies appear and are detectable at different stages of the infection. Early in the infection, HIV-1 antigen can be detected prior to the development of detectable levels of HIV-1 antibodies. Acute HIV-1 infection is identified when the blood specimen is positive for HIV-1 p24 antigen, but is negative for HIV-1 and HIV-2 antibodies.
The BioPlex 2200 HIV Ag-Ab assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA), is to aid in the diagnosis of infection with HIV-1 and/or HIV-2, including acute HIV-1 infection. It may be used in adults, children two years of age and older, as well as in pregnant women. The assay may also be used to screen organ donors for HIV-1/2 when the blood specimen is collected while the donor's heart is still beating. However, the assay is not approved for use in screening blood or plasma donors, except in urgent situations where traditional licensed blood donor screening tests are unavailable or their use is impractical.
The Bio-Rad BioPlex 2200 HIV Ag-Ab assay has been approved by the US Food and Drug Administration (Silver Springs, MD, USA). The assay allows results of antigen and antibody detection to be reported separately. In addition to distinguishing between established HIV-1 and HIV-2 infection, reporting of distinct results helps differentiate between acute and established HIV infection respectively. The BioPlex 2200 HIV Ag-Ab assay is intended for use with the BioPlex 2200 System.
Related Links:
Bio-Rad Laboratories, Inc.
US Food and Drug Administration
Two major types of HIV have been identified: HIV-1 and HIV-2. HIV-1 is responsible for most HIV infections throughout the world. HIV-2 is found primarily in West Africa; however, cases of HIV-2 infection have been identified in the USA. HIV-1 and HIV-2 are similar, but distinct viruses.
HIV antigens and antibodies appear and are detectable at different stages of the infection. Early in the infection, HIV-1 antigen can be detected prior to the development of detectable levels of HIV-1 antibodies. Acute HIV-1 infection is identified when the blood specimen is positive for HIV-1 p24 antigen, but is negative for HIV-1 and HIV-2 antibodies.
The BioPlex 2200 HIV Ag-Ab assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA), is to aid in the diagnosis of infection with HIV-1 and/or HIV-2, including acute HIV-1 infection. It may be used in adults, children two years of age and older, as well as in pregnant women. The assay may also be used to screen organ donors for HIV-1/2 when the blood specimen is collected while the donor's heart is still beating. However, the assay is not approved for use in screening blood or plasma donors, except in urgent situations where traditional licensed blood donor screening tests are unavailable or their use is impractical.
The Bio-Rad BioPlex 2200 HIV Ag-Ab assay has been approved by the US Food and Drug Administration (Silver Springs, MD, USA). The assay allows results of antigen and antibody detection to be reported separately. In addition to distinguishing between established HIV-1 and HIV-2 infection, reporting of distinct results helps differentiate between acute and established HIV infection respectively. The BioPlex 2200 HIV Ag-Ab assay is intended for use with the BioPlex 2200 System.
Related Links:
Bio-Rad Laboratories, Inc.
US Food and Drug Administration
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms